Partners and Collaborators
The George Washington University
The George Washington University School of Medicine and Health Sciences is the primary academic affiliation for faculty at Children’s National Health System. The Department of Pediatrics in the George Washington University School of Medicine and Health Sciences is dedicated to improving the health and well-being of all children through superior research, education, and outreach. Housed at Children’s National Health System (formerly Children's National Medical Center), the department’s cutting-edge technology, innovative practices, and renowned physicians and researchers provide students and faculty with an unmatched environment to learn and grow.
Urea Cycle Disorders Consortium
The Urea Cycle Disorders Consortium (UCDC) is a team of doctors, nurses, research coordinators, and research labs throughout the US, working together to improve the lives of people with Urea Cycle Disorders. Since Urea Cycle Disorders are rare, there are low numbers of research participants and this adds a greater level of difficulty for researchers struggling to learn more about these disorders. The purpose of this consortium is to provide a way for patients to join with doctors and researchers by participating in research studies. The greater the collaboration between doctors and patients, the more we can learn about Urea Cycle Disorders. This important first step is necessary if we are ever to find newer treatments.
Mark Batshaw, MD, Mendel Tuchman, MD, and Marshall Summar, MD, established the UCDC in 2003 through an National Institutes of Health grant that established the Rare Diseases Clinical Research Network. The UCDC was one of the ten original consortia of the RDCRN, which has now grown to include 17 research consortia focusing on rare diseases.
The Cooperative International Neuromuscular Research Group (CINRG)
CINRG was formed in 1999 as the clinical research arm of the Duchenne Muscular Dystrophy Research Center and the Center for Genetic Medicine Research at Children's National Health System. The program provides a continuum of well-designed clinical trials in a geographically dispersed network of clinics that make trials available to every child with Duchenne muscular dystrophy around the world.